Jürgen Brockmöller
Jürgen Brockmöller
Professor of Clinical Pharmacology, Georg August University Göttingen
Verified email at - Homepage
Cited by
Cited by
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
S Hoffmeyer, O Burk, O Von Richter, HP Arnold, J Brockmöller, A Johne, ...
Proceedings of the National Academy of Sciences 97 (7), 3473-3478, 2000
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
C Sachse, J Brockmöller, S Bauer, I Roots
American journal of human genetics 60 (2), 284, 1997
Metabolic gene polymorphism frequencies in control populations
Cancer Epidemiology, Biomarkers & Prevention 10 (12), 1239-1248, 2001
Low intensity transcranial electric stimulation: safety, ethical, legal regulatory and application guidelines
A Antal, I Alekseichuk, M Bikson, J Brockmöller, AR Brunoni, R Chen, ...
Clinical neurophysiology 128 (9), 1774-1809, 2017
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
J Kirchheiner, K Nickchen, M Bauer, ML Wong, J Licinio, I Roots, ...
Molecular psychiatry 9 (5), 442-473, 2004
Functional significance of a C→ A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
C Sachse, J Brockmöller, S Bauer, I Roots
British journal of clinical pharmacology 47 (4), 445-449, 1999
The genetic determinants of the CYP3A5 polymorphism
E Hustert, M Haberl, O Burk, R Wolbold, YQ He, K Klein, AC Nuessler, ...
Pharmacogenetics and Genomics 11 (9), 773-779, 2001
Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)
A Johne, J Brockmöller, S Bauer, A Maurer, M Langheinrich, I Roots
Clinical Pharmacology & Therapeutics 66 (4), 338-345, 1999
Clinical consequences of cytochrome P450 2C9 polymorphisms
J Kirchheiner, J Brockmöller
Clinical Pharmacology & Therapeutics 77 (1), 1-16, 2005
Nomenclature for human CYP2D6 alleles
AK Daly, J Brockmoller, F Broly, M Eichelbaum, WE Evans, FJ Gonzalez, ...
Pharmacogenetics and Genomics 6 (3), 193-201, 1996
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages
J Kirchheiner, K Brøsen, ML Dahl, LF Gram, S Kasper, I Roots, F Sjöqvist, ...
Acta Psychiatrica Scandinavica 104 (3), 173-192, 2001
NAD (P) H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
L Wojnowski, B Kulle, M Schirmer, G Schlüter, A Schmidt, ...
Circulation 112 (24), 3754-3762, 2005
Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines
S Rossi, A Antal, S Bestmann, M Bikson, C Brewer, J Brockmöller, ...
Clinical Neurophysiology 132 (1), 269-306, 2021
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
J Kirchheiner, H Schmidt, M Tzvetkov, J Keulen, J Lötsch, I Roots, ...
The pharmacogenomics journal 7 (4), 257-265, 2007
Combined Analysis of Inherited Polymorphisms in Arylamine N-Acetyltransferase 2, Glutathione S-Transferases M1 and T1, Microsomal Epoxide Hydrolase, and …
J Brockmöller, I Cascorbi, R Kerb, I Roots
Cancer Research 56 (17), 3915-3925, 1996
A C4887A Polymorphism in Exon 7 of Human CYP1A1: Population Frequency, Mutation Linkages, and Impact on Lung Cancer Susceptibility
I Cascorbi, J Brockmöller, I Roots
Cancer research 56 (21), 4965-4969, 1996
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
EA Gaikovitch, I Cascorbi, PM Mrozikiewicz, J Brockmöller, R Frötschl, ...
European journal of clinical pharmacology 59, 303-312, 2003
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.
I Cascorbi, N Drakoulis, J Brockmöller, A Maurer, K Sperling, I Roots
American journal of human genetics 57 (3), 581, 1995
Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene
A Johne, K Köpke, T Gerloff, I Mai, S Rietbrock, C Meisel, S Hoffmeyer, ...
Clinical Pharmacology & Therapeutics 72 (5), 584-594, 2002
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA
I Koch, R Weil, R Wolbold, J Brockmöller, E Hustert, O Burk, A Nuessler, ...
Drug Metabolism and Disposition 30 (10), 1108-1114, 2002
The system can't perform the operation now. Try again later.
Articles 1–20